WO2022042643A1 - 卡利拉嗪药用盐及其晶型、制备方法和应用 - Google Patents

卡利拉嗪药用盐及其晶型、制备方法和应用 Download PDF

Info

Publication number
WO2022042643A1
WO2022042643A1 PCT/CN2021/114756 CN2021114756W WO2022042643A1 WO 2022042643 A1 WO2022042643 A1 WO 2022042643A1 CN 2021114756 W CN2021114756 W CN 2021114756W WO 2022042643 A1 WO2022042643 A1 WO 2022042643A1
Authority
WO
WIPO (PCT)
Prior art keywords
cariprazine
acid
pamoate
crystal form
characteristic peaks
Prior art date
Application number
PCT/CN2021/114756
Other languages
English (en)
French (fr)
Inventor
应述欢
陈志祥
张贤
朱涛
王婷婷
刘爽
Original Assignee
上海博志研新药物技术有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海博志研新药物技术有限公司 filed Critical 上海博志研新药物技术有限公司
Priority to US18/043,000 priority Critical patent/US20230355612A1/en
Priority to JP2023513724A priority patent/JP2023540056A/ja
Priority to EP21860477.5A priority patent/EP4206191A1/en
Publication of WO2022042643A1 publication Critical patent/WO2022042643A1/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the present invention relates to a medicinal salt of cariprazine and its crystal form, preparation method and application.
  • Cariprazine (Formula I) is a novel atypical antipsychotic drug with antagonistic effects on dopamine D3, dopamine D2 and serotonin 2B receptors. It can be used for the treatment of schizophrenia and type 1 double disorder. Cariprazine hydrochloride capsules are currently on the market. This product is an oral preparation and needs to be administered daily to maintain its blood drug concentration. However, due to the need for frequent administration, the patient's medication compliance is poor.
  • Patent document CN101679315A discloses various salts of cariprazine, including monohydrochloride, dihydrochloride, monohydrobromide, maleate and mesylate.
  • Patent document CN105218484A discloses cariprazine tartrate, and provides cariprazine tartrate, cariprazine hydrochloride, cariprazine maleate, cariprazine benzene sulfonate and cariprazine The solubility of pyrazine phosphate is greater than 3 mg/mL.
  • Patent document WO2020056929A discloses a new crystal form of cariprazine hydrochloride, which mentions that cariprazine hydrochloride dissociates quickly into free base in pH 6.5 buffer.
  • the present invention provides a medicinal salt of cariprazine
  • the medicinal salt of cariprazine is selected from the salt formed by the free base I of cariprazine and an organic acid having more than six carbons.
  • the organic acids with more than six carbons include, but are not limited to: caproic acid, heptanoic acid, caprylic acid, nonanoic acid, azelaic acid, capric acid, sebacic acid, undecanoic acid, lauric acid acid (dodecanoic acid), tridecanoic acid, myristic acid (tetradecanoic acid), pentadecanoic acid, palmitic acid (i.e.
  • palmitic or hexadecanoic acid palmitic or hexadecanoic acid
  • heptadecanoic acid stearic acid (octadecanoic acid), nonadecanoic acid, eicosanoic acid (arachidic acid), oleic acid, behenic acid, behenic acid, behenic acid, behenic acid, behenic acid Pentadecanoic acid, hexadecanoic acid, heptacosanoic acid, octacosanoic acid, nonacosanoic acid, triacontanoic acid (mellitic acid), triglyceride, lignin, pamoic acid (palmitate), 1-hydroxy-2-naphthoic acid, pamoic acid, and naphthoic acid derivatives (including but not limited to naphthoate).
  • the palmitate refers to a structure after palmitic acid is esterified with at least one hydroxyl group of a compound containing both carboxyl and hydroxyl groups (such as pamoic acid);
  • the naphthalate refers to naphthalene A structure in which an acid is esterified with at least one hydroxyl group of a compound containing both carboxyl and hydroxyl groups, such as pamoic acid.
  • the pamoic acid is also called Pamoic acid, CAS No. 130-85-8.
  • the molar ratio of cariprazine to organic acid in the pharmaceutically acceptable salt may be (1:0.5) ⁇ (1:2).
  • the pharmaceutically acceptable salt of cariprazine may be cariprazine monopamoate, cariprazine hemipamoate, cariprazine 1-hydroxy-2-naphthalene Formate, cariprazine laurate, cariprazine palmitate, cariprazine sebacate, cariprazine undecanoate or cariprazine enanthate.
  • the Pamoic acid is Pamoic acid, also known as Pamoic acid, CAS No. 130-85-8.
  • the pharmaceutically acceptable salt of cariprazine may be in crystalline, polymorphic or amorphous form.
  • polymorphism refers to different crystal forms and other solid-state molecular forms of the same compound, for example, comprising two or more crystal forms of the pharmaceutically acceptable salt of cariprazine and/or solid in amorphous form.
  • the pharmaceutically acceptable salt of cariprazine includes its solvate with a solvent.
  • the solvates include hydrates of pharmaceutically acceptable salts of cariprazine and solvates formed by pharmaceutically acceptable salts of cariprazine and organic solvents.
  • the "organic solvent” mentioned in the "solvate formed by a pharmaceutically acceptable salt of cariprazine and an organic solvent” includes but is not limited to a solvent selected from ethanol, acetone, dimethyl sulfoxide and mixtures thereof.
  • the present invention also provides the preparation method of the described cariprazine medicinal salt, which comprises the following steps: reacting the cariprazine free base with the organic acid with more than six carbons (as in and reaction) to obtain the pharmaceutically acceptable salt of cariprazine.
  • the preparation method of the pharmaceutically acceptable salt of cariprazine can be carried out in a solvent or under a solvent-free condition.
  • the organic acid with more than six carbons can be a C 6 -C 30 organic acid.
  • the C6 - C30 organic acids include but are not limited to: caproic acid, heptanoic acid, octanoic acid, nonanoic acid, azelaic acid, capric acid, undecanoic acid, lauric acid (dodecanoic acid), tridecanoic acid Alkanoic acid, myristic acid (tetradecanoic acid), pentadecanoic acid, palmitic acid (hexadecanoic acid), heptadecanic acid, stearic acid (octadecanoic acid), nonadecanoic acid, eicosane acid (arachidic acid), oleic acid, behenic acid, behenic acid, behenic acid, pentadecanoic acid, behenic acid, heptacosanoic acid and
  • the pharmaceutically acceptable salt of cariprazine is cariprazine pamoate.
  • the cariprazine medicinal salt is characterized in that: the cariprazine medicinal salt is cariprazine free base and pamoic acid in a ratio of 1:1 to 2 :1 molar ratio of cariprazine pamoate formed.
  • the preparation method of described cariprazine pamoate adopts any one of the following methods:
  • the first solvent is methanol, ethanol, dichloromethane, acetone, dibutyl ketone, tetrahydrofuran, N,N-dimethylformamide, dimethyl sulfoxide or a mixture thereof, preferably methanol, ethanol, tetrahydrofuran, methyl sulfoxide or a mixture thereof;
  • the second solvent is isopropanol, methyl tert-butyl ether, n-heptane, toluene, isopropyl ether or a mixture thereof, preferably water;
  • the phosphoric acid aqueous solution has a concentration of 1 mg/mL to 6 mg/mL;
  • the concentration of the aqueous sodium hydroxide solution is 1 mg/mL to 8 mg/mL.
  • the cariprazine pamoate is in crystalline, polycrystalline or amorphous form.
  • the cariprazine pamoate crystals are anhydrous, hydrate or solvate.
  • the solvates include, but are not limited to, solvates formed by cariprazine dinaphthoate and one or more of methanol, ethanol, acetonitrile, tetrahydrofuran, and dimethyl sulfoxide.
  • the cariprazine pamoate is Cariprazine pamoate crystal form A.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystalline form A has 2 ⁇ values of 13.1° ⁇ 0.2°, 18.7° ⁇ 0.2°, 21.0° ⁇ 0.2°, etc. There are characteristic peaks.
  • the X-ray powder diffraction pattern of the crystal form A of cariprazine pamoate has 2 ⁇ values of 4.8° ⁇ 0.2°, 13.1° ⁇ 0.2°, 18.7° ⁇ 0.2°, 20.1° ⁇ There are characteristic peaks at 0.2°, 21.0° ⁇ 0.2°, 26.1° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the crystal form A of cariprazine pamoate has 2 ⁇ values of 4.8° ⁇ 0.2°, 9.7 ⁇ 0.2°, 12.3° ⁇ 0.2°, 13.1° ⁇ 0.2 There are characteristic peaks at °, 18.7° ⁇ 0.2°, 20.1° ⁇ 0.2°, 21.0° ⁇ 0.2°, 26.1° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form A has 2 ⁇ values of 4.8° ⁇ 0.2°, 8.2° ⁇ 0.2°, 9.7 ⁇ 0.2°, 11.6° ⁇ 0.2 °, 12.3° ⁇ 0.2°, 13.1° ⁇ 0.2°, 14.7° ⁇ 0.2°, 15.1° ⁇ 0.2°, 16.6° ⁇ 0.2°, 18.7° ⁇ 0.2°, 20.1° ⁇ 0.2°, 20.7° ⁇ 0.2°, There are absorption peaks at 21.0° ⁇ 0.2°, 21.6° ⁇ 0.2°, 22.1° ⁇ 0.2°, 24.1° ⁇ 0.2°, 26.1° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form A is basically as shown in FIG. 2 .
  • the differential scanning calorimetry analysis diagram of the cariprazine pamoate crystal form A is basically as shown in FIG. 3 , showing that the melting point is about 166.5°C.
  • thermogravimetric analysis diagram of the described cariprazine pamoic acid crystal form A is basically as shown in Figure 4, showing that there are two stages of weight loss before 115 ° C, due to the loss of surface solvent and channel water, at 115 ⁇ 165 At °C, there is a weight loss of about 1.1%, which is attributed to the loss of crystal water.
  • the NMR chart of the described cariprazine pamoic acid crystal form A is basically as shown in FIG. 5 , which shows that cariprazine and pamoic acid form a salt in a molar ratio of 1:1.
  • the preparation method of described cariprazine pamoate crystal form A is as follows:
  • the solvent is methanol
  • the good solvent is dibutyl ketone
  • the anti-solvent is n-heptane.
  • the cariprazine pamoate salt is the crystalline form F of cariprazine pamoate salt.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystalline form F has 2 ⁇ values of 4.9° ⁇ 0.2°, 19.2° ⁇ 0.2°, 21.0° ⁇ 0.2°, etc. There are characteristic peaks.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form F has 2 ⁇ values of 4.9° ⁇ 0.2°, 13.6° ⁇ 0.2°, 19.2° ⁇ 0.2°, 21.0° ⁇ 0.2 There are characteristic peaks at °, 24.0° ⁇ 0.2°, 26.3° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form F has 2 ⁇ values of 4.9° ⁇ 0.2°, 12.8° ⁇ 0.2°, 13.6° ⁇ 0.2°, 19.2° ⁇ 0.2 There are characteristic peaks at °, 20.3° ⁇ 0.2°, 21.0° ⁇ 0.2°, 24.0° ⁇ 0.2°, 26.3° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystalline form F has 2 ⁇ values of 4.9° ⁇ 0.2°, 8.4° ⁇ 0.2°, 9.7 ⁇ 0.2°, 10.4° ⁇ 0.2°, 11.6° ⁇ 0.2°, 12.8° ⁇ 0.2°, 13.3° ⁇ 0.2°, 13.6° ⁇ 0.2°, 15.0° ⁇ 0.2°, 15.4° ⁇ 0.2°, 16.8° ⁇ 0.2° , 17.0° ⁇ 0.2°, 18.5° ⁇ 0.2°, 18.8° ⁇ 0.2°, 19.2° ⁇ 0.2°, 19.5° ⁇ 0.2°, 20.3° ⁇ 0.2°, 21.0° ⁇ 0.2°, 21.9° ⁇ 0.2°, 22.2 ° ⁇ 0.2°, 22.5° ⁇ 0.2°, 24.0° ⁇ 0.2°, 25.1° ⁇ 0.2°, 25.7° ⁇ 0.2°, 26.3° ⁇ 0.2°, 26.8° ⁇ 0.2°, 28.8° ⁇ 0.2°, 29.6° ⁇ There are characteristic peaks at 0.2° and so on.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form F is basically shown in FIG. 6 .
  • the differential scanning calorimetry analysis diagram of the cariprazine pamoate crystalline form F is basically as shown in FIG. 7 , showing that the melting point is about 166.6°C.
  • thermogravimetric analysis diagram of the described cariprazine pamoic acid crystal form F is basically as shown in Figure 8, showing that there is about 1.3% weight loss before 115 ° C, which is due to the loss of channel water; at 115 ⁇ 175 ° C There is a weight loss of about 1.3% due to the loss of crystal water.
  • the NMR image of the described cariprazine pamoic acid crystal form F is basically as shown in FIG. 9 , which shows that cariprazine and pamoic acid form a salt in a molar ratio of 1:1.
  • the preparation method of described cariprazine pamoate crystal form F is as follows:
  • the cariprazine pamoate crystal form A is formed into a slurry in a solvent, and the crystal form F is obtained by stirring and crystallization;
  • the solvent is ethyl acetate, isopropyl acetate, methyl tert-butyl ether or n-heptane.
  • the cariprazine pamoate salt is the crystalline form D of cariprazine pamoate salt.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystalline form D has 2 ⁇ values of 9.6° ⁇ 0.2°, 11.9° ⁇ 0.2°, 20.4° ⁇ 0.2°, etc. There are characteristic peaks.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form D has 2 ⁇ values of 9.6° ⁇ 0.2°, 11.9° ⁇ 0.2°, 16.6° ⁇ 0.2°, 20.4° ⁇ 0.2 There are characteristic peaks at °, 24.5° ⁇ 0.2°, 25.3° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form D has 2 ⁇ values of 9.6° ⁇ 0.2°, 11.9° ⁇ 0.2°, 15.2° ⁇ 0.2°, 16.6° ⁇ 0.2 There are characteristic peaks at °, 20.4° ⁇ 0.2°, 20.7° ⁇ 0.2°, 24.5° ⁇ 0.2°, 25.3° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form D has 2 ⁇ values of 9.6° ⁇ 0.2°, 10.1° ⁇ 0.2°, 10.5 ⁇ 0.2°, 11.9° ⁇ 0.2°, 13.2° ⁇ 0.2°, 14.5° ⁇ 0.2°, 15.2° ⁇ 0.2°, 16.6° ⁇ 0.2°, 20.4° ⁇ 0.2°, 20.7° ⁇ 0.2°, 21.1° ⁇ 0.2° , 21.9° ⁇ 0.2°, 23.5° ⁇ 0.2°, 18.8° ⁇ 0.2°, 19.2° ⁇ 0.2°, 19.5° ⁇ 0.2°, 20.3° ⁇ 0.2°, 21.0° ⁇ 0.2°, 24.5° ⁇ 0.2°, 25.3 There are characteristic peaks at ° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form D is basically shown in FIG. 10 .
  • the differential scanning calorimetry analysis diagram of the cariprazine pamoate crystal form D is basically as shown in FIG. 11 , showing that the melting point is about 164.6°C.
  • thermogravimetric analysis diagram of the described cariprazine pamoic acid crystal form D is basically as shown in FIG. 12 , which shows that there is about 4% weight loss before 190° C., which is due to the loss of water and ethanol.
  • the NMR image of the described cariprazine pamoic acid crystal form D is basically as shown in FIG. 13 , which shows that cariprazine and pamoic acid form a salt in a molar ratio of 1:1.
  • the preparation method of described cariprazine pamoate crystal form D is as follows:
  • the cariprazine pamoate crystal form D is obtained by stirring and crystallization of cariprazine pamoate in ethanol.
  • the cariprazine pamoate salt is the crystal form B of cariprazine pamoate salt.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystalline form B has 2 ⁇ values of 5.2° ⁇ 0.2°, 10.5° ⁇ 0.2°, 14.0° ⁇ 0.2°, There are characteristic peaks at 14.4° ⁇ 0.2°, 17.5° ⁇ 0.2°, 21.3° ⁇ 0.2°, 21.9° ⁇ 0.2°, 22.9° ⁇ 0.2°, 26.2° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form B is basically as shown in FIG. 14 .
  • the cariprazine pamoate salt is the crystal form C of cariprazine pamoate salt.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystalline form C has 2 ⁇ values of 8.6° ⁇ 0.2°, 13.0° ⁇ 0.2°, 16.8° ⁇ 0.2°, There are characteristic peaks at 17.3° ⁇ 0.2°, 18.2° ⁇ 0.2°, 18.5° ⁇ 0.2°, 19.8° ⁇ 0.2°, 22.1° ⁇ 0.2°, 23.5° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form C is basically shown in FIG. 15 .
  • the cariprazine pamoate salt is the crystal form E of cariprazine pamoate salt.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystalline form E has 2 ⁇ values of 11.0° ⁇ 0.2°, 12.8° ⁇ 0.2°, 13.8° ⁇ 0.2°, There are characteristic peaks at 15.5° ⁇ 0.2°, 15.9° ⁇ 0.2°, 17.9° ⁇ 0.2°, 18.4° ⁇ 0.2°, 20.7° ⁇ 0.2°, 23.4° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form E is basically shown in FIG. 16 .
  • the cariprazine pamoate salt is the crystal form G of cariprazine pamoate salt.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystalline form G has 2 ⁇ values of 8.7° ⁇ 0.2°, 10.0° ⁇ 0.2°, 13.6° ⁇ 0.2°, There are characteristic peaks at 14.3° ⁇ 0.2°, 17.5° ⁇ 0.2°, 18.0° ⁇ 0.2°, 20.3° ⁇ 0.2°, 23.2° ⁇ 0.2°, 25.1° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form G is basically as shown in FIG. 17 .
  • the cariprazine pamoate salt is the crystal form I of cariprazine pamoate salt.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystalline form I has 2 ⁇ values of 10.0° ⁇ 0.2°, 14.9° ⁇ 0.2°, 16.3° ⁇ 0.2°, There are characteristic peaks at 17.7° ⁇ 0.2°, 18.5° ⁇ 0.2°, 19.0° ⁇ 0.2°, 21.1° ⁇ 0.2°, 22.1° ⁇ 0.2°, 24.5° ⁇ 0.2°, etc.
  • the X-ray powder diffraction pattern of the cariprazine pamoate crystal form I is basically as shown in FIG. 18 .
  • the term "solvate” includes a molecular complex of a drug and a stoichiometric or non-stoichiometric amount of one or more solvent molecules (eg, ethanol).
  • solvent molecules eg, ethanol
  • the solvent content will depend on humidity and drying conditions. In such cases, the complex will generally be non-stoichiometric.
  • the term “hydrate” describes a solvate comprising a drug with a stoichiometric or non-stoichiometric amount of water.
  • relative humidity refers to the ratio, expressed as a percentage, of the amount of water vapor at a specified temperature to the maximum amount of water vapor that can be held at that temperature and pressure.
  • the reagents and raw materials used in the present invention are all commercially available.
  • the room temperature refers to an ambient temperature ranging from 10°C to 35°C.
  • the inventors unexpectedly found that the cariprazine medicinal salt disclosed in the prior art is too soluble, and the cariprazine hydrochloride has an unsatisfactory aqueous solution stability, and will rapidly dissociate into a weakly acidic or alkaline environment. Free base and other shortcomings, so this type of salt is not suitable for long-acting sustained-release preparations.
  • the cariprazine medicinal salt of the present invention improves the above-mentioned problems, and its properties such as low solubility, good crystal form stability, good storage stability, no dissociation, easy processing and the like are more conducive to the preparation of long-acting sustained-release preparations, and the market The prospect of chemicalization is good.
  • Fig. 1 is the XRPD spectrum of cariprazine pamoate amorphous
  • Fig. 2 is the XRPD spectrum of cariprazine pamoate crystal form A
  • Fig. 3 is the DSC spectrum of cariprazine pamoate crystal form A
  • Fig. 4 is the TGA spectrum of cariprazine pamoate crystal form A
  • Fig. 5 is the 1 H-NMR spectrum of cariprazine pamoate crystal form A
  • Fig. 6 is the XRPD spectrum of cariprazine pamoate crystal form F
  • Fig. 7 is the DSC spectrum of cariprazine pamoate crystal form F
  • Fig. 8 is the TGA spectrum of cariprazine pamoate crystal form F
  • Fig. 9 is the 1 H-NMR spectrum of cariprazine pamoate crystal form F.
  • Fig. 10 is the XRPD spectrum of cariprazine pamoate crystal form D
  • Fig. 11 is the DSC spectrum of cariprazine pamoate crystal form D;
  • Figure 12 is the TGA spectrum of cariprazine pamoate crystal form D
  • Figure 13 is the 1 H-NMR spectrum of cariprazine pamoate crystal form D;
  • Figure 14 is the XRPD pattern of cariprazine pamoate crystal form B
  • Fig. 15 is the XRPD pattern of cariprazine pamoate crystal form C
  • Figure 16 is the XRPD pattern of cariprazine pamoate crystal form E
  • Figure 17 is the XRPD pattern of cariprazine pamoate crystal form G
  • Figure 18 is the XRPD pattern of cariprazine pamoate crystal form I;
  • Figure 19 is the XRPD pattern of cariprazine hydrochloride crystal form I;
  • Figure 20 is a graph showing the results of the in vitro dissolution simulation experiment ( ⁇ is the amorphous form of cariprazine pamoate; ⁇ is the crystalline form A of cariprazine pamoate; ⁇ is cariprazine pamoate Crystal form B; ⁇ is cariprazine pamoate crystal form G);
  • Figure 21 is the XRPD spectrum overlay of cariprazine pamoate and cariprazine hydrochloride under the condition of pH 7.4 in Comparative Example 4 (A is cariprazine free base; B is cariprazine free base; Hydrochloride Form I; C: Cariprazine Hydrochloride Form I after shaking in pH 7.4; D: Cariprazine Pamoate Form A; E: Cariprazine Pamoate Naphthoate crystal form A after shaking in pH 7.4 medium).
  • Figure 22 depicts the relationship between the average blood concentration of cariprazine and time in the oral sample of the preparation of Example 44 of the present invention in rats;
  • Figure 23 depicts the relationship between the average blood concentration of cariprazine and time in the injection samples of the preparations of Examples 40-43 of the present invention in rats ( ⁇ is cariprazine pamoate amorphous; ⁇ is Cariprazine pamoate crystal form A; ⁇ is cariprazine pamoate crystal form B; ⁇ is cariprazine pamoate crystal form E);
  • Figure 24 Partial magnified view of Figure 23 (the relationship between the average blood concentration of cariprazine and time from 0 to 24 hours) ( ⁇ is cariprazine pamoate amorphous; ⁇ is cariprazine Pamoate crystalline form A; ⁇ is cariprazine pamoate crystalline form B; ⁇ is cariprazine pamoate crystalline form E).
  • the TGA measurement was performed in a TA Instruments model Q500 device, and the sample (about 2-5 mg) was weighed in an aluminum pan and transferred to the instrument for measurement.
  • the test parameters are as follows: the instrument is heated to 350°C at a rate of 10°C/min, data is collected, and the experimental atmosphere is nitrogen.
  • XRPD measurements were performed in a Bruker model D8 Advance X-ray powder diffractometer using a circular zero-background single crystal silicon sample stage.
  • the scanning parameters are as follows: voltage 40kv, current 40mA, scanning range 3°-45°, scanning step size 0.02°, and scanning mode is continuous scanning.
  • the PLM measurement was carried out in a hot-stage polarizing microscope with Shanghai Dianying Optical Instrument Model DYP990/TPH350, and a small amount of samples were dispersed in a glass slide and photographed in a 10x eyepiece and a 5-40x objective.
  • the detection conditions of the particle size detection instrument for the suspension aqueous solution of cariprazine pharmaceutical composition are as follows:
  • solution B Dissolve 4000mg (9.36mmol) cariprazine in 200mL (5.4mg/mL) phosphoric acid solution to obtain solution A; dissolve 3634mg (9.36mmol) pamoic acid in 100mL (7.5mg/mL) sodium hydroxide solution , solution B was obtained. Under stirring, 100 mL of solution B was added to 200 mL of solution A within 30 minutes, the product was isolated by filtration, washed with water, and dried under vacuum at 40°C for 12 hours to obtain 5840 mg of pale yellow solid with a yield of 76% (based on free base).
  • cariprazine pamoate of the present invention was confirmed by proton nuclear magnetic resonance spectrum.
  • solution A Dissolve 200 mg (0.468 mmol) of cariprazine in 10 mL (5.4 mg/mL) of phosphoric acid solution to obtain solution A; dissolve 90.85 mg (0.234 mmol) of pamoic acid in 2.5 mL (7.5 mg/mL) of hydrogen peroxide In sodium solution, solution B was obtained. Under stirring, 2.5 mL of solution B was added to 10 mL of solution A within 30 minutes, the product was isolated by filtration, washed with water, and dried under vacuum at 40° C. for 12 hours to obtain 204 mg of pale yellow solid with a yield of 70%.
  • cariprazine pamoate of the present invention was confirmed by proton nuclear magnetic resonance spectrum.
  • cariprazine laurate 50 mg (0.117 mmol) of cariprazine and 23.7 mg (0.118 mmol) of lauric acid were added to 5 mL of methanol, dissolved at 50 °C, stirred at room temperature for 12 hours, added with 2 times the volume of water, filtered, and the solid was heated at 40 °C Dry under vacuum for 12 hours to obtain cariprazine laurate.
  • Example 7 Cariprazine Sebacate, Cariprazine Succinate, Cariprazine Malate, Cariprazine Lactate, Cariprazine Undecanoate, Cariprazine Preparation of azine heptanoate
  • Cariprazine and acid were weighed in a molar ratio of 1:1.1.
  • Various acids were dissolved in methanol solvent respectively, and the obtained acidic reagent was added to cariprazine methanol solution at room temperature to carry out salt-forming reaction. After stirring at room temperature for 12 hours, it was evaporated and dried at room temperature to obtain the corresponding cariprazine salt.
  • cariprazine pamoate prepared in Example 1 Take 2000 mg of cariprazine pamoate prepared in Example 1, add it to 20 mL of methanol, stir and crystallize at room temperature for 24 hours, filter, and vacuum dry at 55 °C to obtain 1900 mg of cariprazine pamoate crystal form A, the yield is 95%.
  • thermogravimetric analysis diagram is shown in Figure 4, which shows that there are two stages of weight loss before 115 °C, which is due to the loss of surface solvent and channel water. loss.
  • cariprazine pamoate crystal form A prepared in Example 8, add it to 2 mL of ethanol, stir and crystallize at room temperature for 48 hours, filter, and vacuum dry at 55 °C to obtain 190 mg of cariprazine pamoic acid.
  • Salt crystal form D the yield is 95%.
  • thermogravimetric analysis profile is shown in Figure 12, showing a weight loss of about 4% before 190°C, due to the loss of water and ethanol.
  • cariprazine pamoate crystalline form A prepared in Example 8, add it to 20 mL of isopropyl acetate, stir and crystallize at room temperature for 12 hours, filter, and vacuum dry at 55 °C to obtain 180 mg of cariprazine bisulfite. Hydroxynaphthate crystal form F, the yield is 90%.
  • thermogravimetric analysis diagram is shown in Figure 8, which shows that there is about 1.3% weight loss before 115°C, which is due to the loss of channel water; about 1.3% weight loss at 115-175°C, which is due to the loss of crystal water.
  • cariprazine pamoate crystal form A obtained in Example 8, add 5 mL of acetonitrile to form a slurry, and stir for 5 days for crystallization to obtain cariprazine pamoate crystal form G.
  • Comparative Example 1 Comparison of the stability of related substances and crystal forms
  • cariprazine pamoate amorphous form prepared in Example 1 Take the cariprazine pamoate amorphous form prepared in Example 1, the cariprazine pamoate crystal form A prepared in Example 8, and the cariprazine pamoate crystalline form A prepared in Example 10, respectively.
  • the crystalline form B of cariprazine pamoate, the crystalline form F of cariprazine pamoate prepared in Example 16, the crystalline form G of cariprazine pamoate prepared in Example 17, and the crystalline form G of cariprazine pamoate prepared in Example 19 The obtained cariprazine hydrochloride crystal form I was exposed to high temperature (60°C), high humidity (25°C/90%RH), accelerated (40°C/75%RH), light (1.2 ⁇ 10 6 Lux ⁇ hr) Placed under conditions, samples were taken at 0 days, 5 days, 7 days and 10 days for HPLC or XRPD detection.
  • the crystal form stability results are shown in Table 2, which shows that compared with the known cariprazine hydrochloride crystal form I, the cariprazine pamoate crystal form A of the present invention has more excellent crystal form stability When placed under various conditions for 10 days, the crystal form does not change, and the crystallinity does not change significantly; the cariprazine pamoate crystal form F of the present invention is relatively stable under high temperature and light conditions, and the crystal form does not occur. changes, will convert to Cariprazine Pamoate Form A under high humidity and accelerated conditions.
  • cariprazine pamoate amorphous prepared in Example 1 Take the cariprazine pamoate amorphous prepared in Example 1, the cariprazine semi-pamoate amorphous prepared in Example 3, and the cariprazine lauric acid prepared in Example 5.
  • Salt Cariprazine Palmitate prepared in Example 6, Cariprazine Sebacate prepared in Example 7, Cariprazine Succinate, Cariprazine Malate, Cariprazine Perazine Lactate, Cariprazine Undecanoate, Cariprazine Enanthate, Cariprazine Pamoate Crystal Form A Prepared in Example 8, Cariprazine Pamoate Crystal Form A Prepared in Example 10
  • Cariprazine pamoate crystal form B Cariprazine pamoate crystal form F prepared in Example 16
  • Cariprazine pamoate crystal form G prepared in Example 17, Cariprazine hydrochloride crystal form I and cariprazine prepared in Example 19 were respectively added to the corresponding medium, shaken at 37° C.
  • pH3, pH4, pH5 and pH6 are acetate buffer solutions, and pH7, pH7.4, pH8 and pH9 are phosphate buffer solutions.
  • cariprazine pamoate amorphous form prepared in Example 1 Take the cariprazine pamoate amorphous form prepared in Example 1, the cariprazine pamoate crystal form A prepared in Example 8, and the cariprazine pamoate crystalline form A prepared in Example 10, respectively.
  • the cariprazine pamoate crystalline form B and the cariprazine pamoate crystalline form G prepared in Example 17 were respectively added to the pH 7.4 phosphate buffer solution medium, shaken at 37°C, and heated at 1 , 3, 5, 7, and 24 hours to check the solubility.
  • the results show that cariprazine pamoate crystal form A has not changed, while cariprazine The hydrochloride salt crystal form I dissociates into cariprazine free base, and the comparison results at pH 7.4 are shown in Figure 21 (the rest are not shown). It can be seen that the cariprazine pamoate crystal form A is in the solution. Compared with cariprazine hydrochloride crystal form I, it is more stable, can effectively avoid the change of drug effect caused by the change of crystal form after administration, and improve the safety of medication.
  • Example 20-25 Cariprazine Pamoate Suspension Aqueous Solution with Different Suspending Agent Amounts
  • the mixed aqueous solution of the same recipe and the same grinding parameters are applicable to different crystal forms of cariprazine pamoate.
  • Example 38 Aqueous suspension of cariprazine hydrochloride
  • Example 39 Stability of Cariprazine Pamoate and Cariprazine Hydrochloride Suspension Aqueous Solution at 60°C
  • the cariprazine pamoate suspension solution is significantly better than the cariprazine hydrochloride suspension solution in terms of the stability of impurities and particle size.
  • (1) take by weighing recipe quantity Tween 20, disodium hydrogen phosphate, sodium dihydrogen phosphate, mannitol, sodium carboxymethyl cellulose and the water for injection of about 60% preparation total amount, stir, dissolve and disperse;
  • 15 male SD rats were divided into five groups, of which four groups were given a single dose of 9 mg/kg by intramuscular injection with different formulations of cariprazine pamoate crystal forms, and the samples were administered at 0, 1h, 3h, and 7h after administration. , 24h, 4d, 7d, 11d, 15d, 20d, 25d, 30d to collect plasma; the remaining group of single-dose 0.3 mg/kg oral gavage was given the prescription sample of cariprazine pamoate crystal form A, and the Plasma was collected at 5 min, 15 min, 30 min, 1, 2, 3, 4, 6, 8, 12 and 24 hours after administration.
  • the animals in the intramuscular injection group were allowed to eat and drink freely, while the animals in the oral gavage group fasted overnight before administration, and resumed their diet 4 hours after administration.
  • Plasma sample collection About 150 ⁇ L of blood was collected from the jugular vein (the whole blood was centrifuged to separate the plasma within 30 minutes) and placed in a test tube containing the anticoagulant EDTA-K2.
  • Plasma sample pretreatment add 200 ⁇ L of internal standard solution (40ng/mL Glipizide acetonitrile solution) to 30 ⁇ L of plasma sample, vortex for 1 min, centrifuge at 5800 rpm for 10 min at 4°C, transfer 100 ⁇ L of supernatant to a new plate, and take 1 ⁇ L The solution was subjected to LC-MS/MS analysis.
  • internal standard solution 40ng/mL Glipizide acetonitrile solution
  • Mobile phase composition Mobile phase A: 0.025% formic acid in water - 1 mM ammonium acetate
  • Injection volume 1 ⁇ L
  • Retention time Cariprazine: 1.16min; Glipizide: 1.22min.
  • the electrospray ion source (Turbo spray) was used in the positive ion detection mode, and the multi-channel reaction monitoring (MRM) mode was selected for secondary mass spectrometry analysis.
  • MRM multi-channel reaction monitoring
  • the oral cariprazine pamoate group was rapidly absorbed within 24 hours after administration, while the cariprazine pamoate injection group was significantly better than the oral group after administration. Sustained release for at least 11 days, combined with species differences, is expected to deliver at least 30 days in humans. At the same time, among the various crystal forms of cariprazine pamoate, the release time of cariprazine pamoate crystal form A is the best.
  • the cariprazine pamoate injection preparation provided by the present invention is prepared into an aqueous suspension
  • the cariprazine pamoate has small particle size, uniform distribution, and good performance. Injectable, and has the characteristics of long-term sustained drug release (at least one week in SD rats).

Abstract

公开了卡利拉嗪药用盐、制备方法、含有其的药物组合物及应用，所述卡利拉嗪药用盐为卡利拉嗪游离碱与六个碳以上的有机酸形成的盐，其溶解度和稳定性均较好，市场化前景良好。

Description

卡利拉嗪药用盐及其晶型、制备方法和应用
本申请要求享有如下在先申请的优先权权益：2020年8月26日向中国国家知识产权局提交的申请号为202010870701.6的中国发明专利申请；2020年8月26日向中国国家知识产权局提交的申请号为202010869671.7的中国发明专利申请；2021年3月26日向中国国家知识产权局提交的申请号为202110324874.2的中国发明专利申请；和2021年3月26日向中国国家知识产权局提交的申请号为202110330670.X的中国发明专利申请。上述在先申请的全文以引用的方式结合至本文。
技术领域
本发明涉及卡利拉嗪药用盐及其晶型、制备方法和应用。
背景技术
卡利拉嗪(式I)是一种新型非典型抗精神病药，对多巴胺D3、多巴胺D2和5-羟色胺2B受体有拮抗作用。可用于精神分裂症及1型双障碍的治疗。目前上市的是盐酸卡利拉嗪胶囊，该产品为口服制剂，需要每日给药，以维持其血药浓度，但由于需要频繁给药，使得患者的用药依从性差。
Figure PCTCN2021114756-appb-000001
专利文献CN101679315A公开了卡利拉嗪的多种盐，包括单盐酸盐、二盐酸盐、单氢溴酸盐、马来酸盐和甲磺酸盐。专利文献CN105218484A公开了卡利拉嗪酒石酸盐，且提供了卡利拉嗪酒石酸盐、卡利拉嗪盐酸盐、卡利拉嗪马来酸盐、卡利拉嗪苯磺酸盐和卡利拉嗪磷酸盐的溶解度，均大于3mg/mL。专利文献WO2020056929A公开了卡利拉嗪盐酸盐的新晶型，其中提到了卡利拉嗪盐酸盐在pH 6.5缓冲液中会很快解离成游离碱。
鉴于现有技术尚存不足，寻找溶解度低且适宜长效给药、稳定性高、临床效果好、 适合于商品化的卡利拉嗪药用盐及其晶型是本领域目前急需解决的技术问题。
发明内容
为改善上述技术问题，本发明提供了一种卡利拉嗪药用盐，所述的卡利拉嗪药用盐选自卡利拉嗪游离碱I与六个碳以上的有机酸形成的盐：
Figure PCTCN2021114756-appb-000002
根据本发明的实施方案，所述的六个碳以上的有机酸包括但不限于：己酸、庚酸、辛酸、壬酸、壬二酸、癸酸、癸二酸、十一烷酸、月桂酸(十二烷酸)、十三烷酸、肉豆蔻酸(十四烷酸)、十五烷酸、软脂酸(即棕榈酸或十六烷酸)、十七烷酸、硬脂酸(十八烷酸)、十九烷酸、二十烷酸(花生酸)、油酸、二十一烷酸、二十二烷酸、二十三烷酸、二十四烷酸、二十五烷酸、二十六烷酸、二十七烷酸、二十八烷酸、二十九烷酸、三十烷酸(蜂花酸)、甘油三乙酸、木质酸、双羟萘酸(棕榈酸酯)、1-羟基-2-萘甲酸、帕莫酸以及萘酸衍生物(包括但不限于萘酸酯)。
根据本发明的实施方案，所述棕榈酸酯是指棕榈酸与既包含羧基又包含羟基的化合物(诸如双羟萘酸)的至少一个羟基成酯后的结构；所述萘酸酯是指萘酸与既包含羧基又包含羟基的化合物(诸如双羟萘酸)的至少一个羟基成酯后的结构。
根据本发明的实施方案，所述的双羟萘酸又称帕莫酸(Pamoic acid)，CAS No.130-85-8。
根据本发明的实施方案，所述的药用盐中卡利拉嗪与有机酸的摩尔比可以为(1：0.5)～(1：2)。
根据本发明的实施方案，所述的卡利拉嗪药用盐可以为卡利拉嗪单帕莫酸盐、卡利拉嗪半帕莫酸盐、卡利拉嗪1-羟基-2-萘甲酸盐、卡利拉嗪月桂酸盐、卡利拉嗪软脂酸盐、卡利拉嗪癸二酸盐、卡利拉嗪十一烷酸盐或卡利拉嗪庚酸盐。
根据本发明的实施方案，所述的帕莫酸为Pamoic acid，又称双羟萘酸，CAS No. 130-85-8。
根据本发明的实施方案，所述的卡利拉嗪药用盐可以为晶体、多晶或无定型的形式。
根据本发明的实施方案，所述的术语“多晶”是指同一化合物的不同晶体形式和其他固态分子形式，例如包含所述的卡利拉嗪药用盐的两种或两种以上晶型和/或无定型形式的固体。
根据本发明的实施方案，所述的卡利拉嗪药用盐包括其与溶剂形成的溶剂合物。所述的溶剂合物包括卡利拉嗪药用盐的水合物和卡利拉嗪药用盐与有机溶剂形成的溶剂合物。所述的“卡利拉嗪药用盐与有机溶剂形成的溶剂合物”中所述的“有机溶剂”包括但不限于选自乙醇、丙酮、二甲基亚砜及其混合物的溶剂。
本发明还提供了所述的卡利拉嗪药用盐的制备方法，其包括以下步骤：将所述的卡利拉嗪游离碱与所述的六个碳以上的有机酸进行反应(如中和反应)得到所述的卡利拉嗪药用盐即可。
所述的卡利拉嗪药用盐的制备方法可以在溶剂中或无溶剂的条件下进行。
所述的卡利拉嗪药用盐的制备方法中，所述的六个碳以上的有机酸可以为C 6～C 30的有机酸。所述的C 6～C 30的有机酸包括但不限于：己酸、庚酸、辛酸、壬酸、壬二酸、癸酸、十一烷酸、月桂酸(十二烷酸)、十三烷酸、肉豆蔻酸(十四烷酸)、十五烷酸、棕榈酸(十六烷酸)、十七烷酸、硬脂酸(十八烷酸)、十九烷酸、二十烷酸(花生酸)、油酸、二十一烷酸、二十二烷酸、二十三烷酸、二十四烷酸、二十五烷酸、二十六烷酸、二十七烷酸、二十八烷酸、二十九烷酸、三十烷酸(蜂花酸)、甘油三乙酸、木质酸、双羟萘酸(棕榈酸酯)、1-羟基-2-萘甲酸以及萘酸衍生物(包括但不限于萘酸酯)。
根据本发明的实施方案，所述的卡利拉嗪药用盐为卡利拉嗪双羟萘酸盐。
根据本发明的实施方案，所述的卡利拉嗪药用盐，其特征在于：所述的卡利拉嗪药用盐为卡利拉嗪游离碱与双羟萘酸以1:1～2:1的摩尔比形成的卡利拉嗪双羟萘酸盐。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐的制备方法，采用下述方法中的任意一种：
(1)将卡利拉嗪与双羟萘酸溶解于第一溶剂中，去除溶剂或添加第二溶剂，得到卡利拉嗪双羟萘酸盐；
所述第一溶剂为甲醇、乙醇、二氯甲烷、丙酮、二丁酮、四氢呋喃、N,N-二甲基甲酰胺、二甲基亚砜或其混合物，优选为甲醇、乙醇、四氢呋喃、二甲基亚砜或其混合物；
所述第二溶剂为异丙醇、甲基叔丁基醚、正庚烷、甲苯、异丙醚或其混合物，优选为水；
(2)将卡利拉嗪溶解于磷酸水溶液中，得到溶液A；将双羟萘酸溶解于氢氧化钠水溶液中，得到溶液B；将溶液B加入溶液A中，搅拌反应，得到卡利拉嗪双羟萘酸盐；
所述磷酸水溶液浓度为1mg/mL～6mg/mL；
优选地，所述氢氧化钠水溶液浓度为1mg/mL～8mg/mL。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐为晶体、多晶或无定型的形式。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶体为无水物、水合物或溶剂合物。所述的溶剂化物包括但不限于卡利拉嗪双萘酸盐与甲醇、乙醇、乙腈、四氢呋喃、二甲基亚砜中的一种或多种形成的溶剂合物。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐为卡利拉嗪双羟萘酸盐晶型A。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型A的X射线粉末衍射图在2θ值为13.1°±0.2°、18.7°±0.2°、21.0°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐的晶型A的X射线粉末衍射图在2θ值为4.8°±0.2°、13.1°±0.2°、18.7°±0.2°、20.1°±0.2°、21.0°±0.2°、26.1°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐的晶型A的X射线粉末衍射图在2θ值为4.8°±0.2°、9.7±0.2°、12.3°±0.2°、13.1°±0.2°、18.7°±0.2°、20.1°±0.2°、21.0°±0.2°、26.1°±0.2°等处有特征峰。
更进一步地，所述的卡利拉嗪双羟萘酸盐晶型A的X射线粉末衍射图在2θ值为4.8°±0.2°、8.2°±0.2°、9.7±0.2°、11.6°±0.2°、12.3°±0.2°、13.1°±0.2°、14.7°±0.2°、15.1°±0.2°、16.6°±0.2°、18.7°±0.2°、20.1°±0.2°、20.7°±0.2°、21.0°±0.2°、21.6°±0.2°、22.1°±0.2°、 24.1°±0.2°、26.1°±0.2°等处有吸收峰。
更进一步地，所述的卡利拉嗪双羟萘酸盐晶型A的X射线粉末衍射图基本如图2所示。
所述的卡利拉嗪双羟萘酸盐晶型A的差式扫描量热分析图基本如图3所示，显示熔点约为166.5℃。
所述的卡利拉嗪双羟萘酸晶型A的热重分析图基本如图4所示，显示在115℃之前有两段失重，归结于表面溶剂和通道水的损失，在115～165℃时，有约1.1％的失重，归结于结晶水的损失。
所述的所述的卡利拉嗪双羟萘酸晶型A的核磁图基本如图5所示，显示卡利拉嗪与双羟萘酸以摩尔比1:1成盐。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型A的制备方法如下：
(1)将卡利拉嗪双羟萘酸盐加入溶剂中，搅拌析晶，得到所述的卡利拉嗪双羟萘酸盐晶型A；
所述溶剂为甲醇；
(2)将卡利拉嗪双羟萘酸盐溶解于良溶剂中，逐渐加入反溶剂，搅拌析晶，得到所述的卡利拉嗪双羟萘酸盐晶型A。
所述良溶剂为二丁酮；
所述反溶剂为正庚烷。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐为卡利拉嗪双羟萘酸盐晶型F。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型F的X射线粉末衍射图在2θ值为4.9°±0.2°、19.2°±0.2°、21.0°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐晶型F的X射线粉末衍射图在2θ值为4.9°±0.2°、13.6°±0.2°、19.2°±0.2°、21.0°±0.2°、24.0°±0.2°、26.3°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐晶型F的X射线粉末衍射图在2θ值为4.9°±0.2°、12.8°±0.2°、13.6°±0.2°、19.2°±0.2°、20.3°±0.2°、21.0°±0.2°、24.0°±0.2°、26.3°±0.2°等处有特征峰。
更进一步地，根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型F的X射线粉末衍射图在2θ值为4.9°±0.2°、8.4°±0.2°、9.7±0.2°、10.4°±0.2°、11.6°±0.2°、12.8°±0.2°、 13.3°±0.2°、13.6°±0.2°、15.0°±0.2°、15.4°±0.2°、16.8°±0.2°、17.0°±0.2°、18.5°±0.2°、18.8°±0.2°、19.2°±0.2°、19.5°±0.2°、20.3°±0.2°、21.0°±0.2°、21.9°±0.2°、22.2°±0.2°、22.5°±0.2°、24.0°±0.2°、25.1°±0.2°、25.7°±0.2°、26.3°±0.2°、26.8°±0.2°、28.8°±0.2°、29.6°±0.2°等处有特征峰。
更进一步地，所述的卡利拉嗪双羟萘酸盐晶型F的X射线粉末衍射图基本如图6所示。
所述的卡利拉嗪双羟萘酸盐晶型F的差式扫描量热分析图基本如图7所示，显示熔点约为166.6℃。
所述的卡利拉嗪双羟萘酸晶型F的热重分析图基本如图8所示，显示在115℃之前有约1.3％的失重，归结于通道水的损失；在115～175℃有约1.3％的失重，归结于结晶水的损失。
所述的所述的卡利拉嗪双羟萘酸晶型F的核磁图基本如图9所示，显示卡利拉嗪与双羟萘酸以摩尔比1:1成盐。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型F的制备方法如下：
将卡利拉嗪双羟萘酸盐晶型A在溶剂中形成浆液，搅拌析晶，得到所述的卡利拉嗪双羟萘酸盐晶型F；
所述溶剂为乙酸乙酯、乙酸异丙酯、甲基叔丁基醚或正庚烷。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐为卡利拉嗪双羟萘酸盐晶型D。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型D的X射线粉末衍射图在2θ值为9.6°±0.2°、11.9°±0.2°、20.4°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐晶型D的X射线粉末衍射图在2θ值为9.6°±0.2°、11.9°±0.2°、16.6°±0.2°、20.4°±0.2°、24.5°±0.2°、25.3°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐晶型D的X射线粉末衍射图在2θ值为9.6°±0.2°、11.9°±0.2°、15.2°±0.2°、16.6°±0.2°、20.4°±0.2°、20.7°±0.2°、24.5°±0.2°、25.3°±0.2°等处有特征峰。
更进一步地，根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型D的X射线粉末衍射图在2θ值为9.6°±0.2°、10.1°±0.2°、10.5±0.2°、11.9°±0.2°、13.2°±0.2°、 14.5°±0.2°、15.2°±0.2°、16.6°±0.2°、20.4°±0.2°、20.7°±0.2°、21.1°±0.2°、21.9°±0.2°、23.5°±0.2°、18.8°±0.2°、19.2°±0.2°、19.5°±0.2°、20.3°±0.2°、21.0°±0.2°、24.5°±0.2°、25.3°±0.2°等处有特征峰。
更进一步地，所述的卡利拉嗪双羟萘酸盐晶型D的X射线粉末衍射图基本如图10所示。
所述的卡利拉嗪双羟萘酸盐晶型D的差式扫描量热分析图基本如图11所示，显示熔点约为164.6℃。
所述的卡利拉嗪双羟萘酸晶型D的热重分析图基本如图12所示，显示在190℃之前有约4％的失重，归结于水和乙醇的损失。
所述的所述的卡利拉嗪双羟萘酸晶型D的核磁图基本如图13所示，显示卡利拉嗪与双羟萘酸以摩尔比1:1成盐。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型D的制备方法如下：
将卡利拉嗪双羟萘酸盐于乙醇中搅拌析晶，得到所述的利拉嗪双羟萘酸盐晶型D。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐为卡利拉嗪双羟萘酸盐晶型B。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型B的X射线粉末衍射图在2θ值为5.2°±0.2°、10.5°±0.2°、14.0°±0.2°、14.4°±0.2°、17.5°±0.2°、21.3°±0.2°、21.9°±0.2°、22.9°±0.2°、26.2°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐晶型B的X射线粉末衍射图基本如图14所示。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐为卡利拉嗪双羟萘酸盐晶型C。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型C的X射线粉末衍射图在2θ值为8.6°±0.2°、13.0°±0.2°、16.8°±0.2°、17.3°±0.2°、18.2°±0.2°、18.5°±0.2°、19.8°±0.2°、22.1°±0.2°、23.5°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐晶型C的X射线粉末衍射图基本如图15所示。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐为卡利拉嗪双羟萘酸盐晶型E。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型E的X射线粉末衍射图在2θ值为11.0°±0.2°、12.8°±0.2°、13.8°±0.2°、15.5°±0.2°、15.9°±0.2°、17.9°±0.2°、18.4°±0.2°、 20.7°±0.2°、23.4°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐晶型E的X射线粉末衍射图基本如图16所示。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐为卡利拉嗪双羟萘酸盐晶型G。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型G的X射线粉末衍射图在2θ值为8.7°±0.2°、10.0°±0.2°、13.6°±0.2°、14.3°±0.2°、17.5°±0.2°、18.0°±0.2°、20.3°±0.2°、23.2°±0.2°、25.1°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐晶型G的X射线粉末衍射图基本如图17所示。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐为卡利拉嗪双羟萘酸盐晶型I。
根据本发明的实施方案，所述的卡利拉嗪双羟萘酸盐晶型I的X射线粉末衍射图在2θ值为10.0°±0.2°、14.9°±0.2°、16.3°±0.2°、17.7°±0.2°、18.5°±0.2°、19.0°±0.2°、21.1°±0.2°、22.1°±0.2°、24.5°±0.2°等处有特征峰。
进一步地，所述的卡利拉嗪双羟萘酸盐晶型I的X射线粉末衍射图基本如图18所示。
根据本发明的实施方案，所述的术语“溶剂合物”包含药物和化学计量或非化学计量量的一种或多种溶剂分子(如乙醇)的分子复合物。当溶剂与药物紧密结合时，所得的复合物会具有与湿度无关的明确限定的化学计量。然而，当溶剂与药物弱结合时，与在通道溶剂合物(channel solvate)和吸湿性化合物中一样，溶剂含量会取决于湿度和干燥条件。在这样的情况下，复合物通常会是非化学计量性的。
根据本发明的实施方案，所述的术语“水合物”描述包含药物与化学计量或非化学计量量的水的溶剂合物。术语“相对湿度”指在指定温度下的水蒸气的量与在该温度和压力下可以保持的水蒸气的最大量的比率，以百分比表示。
在不违背本领域常识的基础上，上述各优选条件，可任意组合，即得本发明各较佳实例。
本发明所用试剂和原料均市售可得。
根据本发明的实施方案，所述的室温是指环境温度为10℃～35℃。
有益效果
本发明人意外地发现，现有技术公开的卡利拉嗪药用盐溶解度过大，且卡利拉嗪盐酸盐存在水溶液稳定性不够理想、弱酸性或碱性环境中会快速解离成游离碱等缺点，故此类盐型不适合用于长效缓释制剂。本发明的卡利拉嗪药用盐改善了上述问题，其溶解度低、晶型稳定性好、储存稳定性好、不发生解离、易加工等性质更有利于制备长效缓释制剂，市场化前景良好。
附图说明
图1为卡利拉嗪双羟萘酸盐无定型的XRPD图谱；
图2为卡利拉嗪双羟萘酸盐晶型A的XRPD图谱；
图3为卡利拉嗪双羟萘酸盐晶型A的DSC图谱；
图4为卡利拉嗪双羟萘酸盐晶型A的TGA图谱；
图5为卡利拉嗪双羟萘酸盐晶型A的 1H-NMR图谱；
图6为卡利拉嗪双羟萘酸盐晶型F的XRPD图谱；
图7为卡利拉嗪双羟萘酸盐晶型F的DSC图谱；
图8为卡利拉嗪双羟萘酸盐晶型F的TGA图谱；
图9为卡利拉嗪双羟萘酸盐晶型F的 1H-NMR图谱；
图10为卡利拉嗪双羟萘酸盐晶型D的XRPD图谱；
图11为卡利拉嗪双羟萘酸盐晶型D的DSC图谱；
图12为卡利拉嗪双羟萘酸盐晶型D的TGA图谱；
图13为卡利拉嗪双羟萘酸盐晶型D的 1H-NMR图谱；
图14为卡利拉嗪双羟萘酸盐晶型B的XRPD图谱；
图15为卡利拉嗪双羟萘酸盐晶型C的XRPD图谱；
图16为卡利拉嗪双羟萘酸盐晶型E的XRPD图谱；
图17为卡利拉嗪双羟萘酸盐晶型G的XRPD图谱；
图18为卡利拉嗪双羟萘酸盐晶型I的XRPD图谱；
图19为卡利拉嗪盐酸盐晶型I的XRPD图谱；
图20为体外溶出模拟实验结果图(■为卡利拉嗪双羟萘酸盐无定型；◆为卡利拉嗪双羟萘酸盐晶型A；●为卡利拉嗪双羟萘酸盐晶型B；▲为卡利拉嗪双羟萘酸盐晶型G)；
图21为对比例4中pH7.4条件下卡利拉嗪双羟萘酸盐与卡利拉嗪盐酸盐的XRPD图谱叠图(A为卡利拉嗪游离碱；B为卡利拉嗪盐酸盐晶型I；C为卡利拉嗪盐酸盐晶型I在pH7.4介质振荡后；D为卡利拉嗪双羟萘酸盐晶型A；E为卡利拉嗪双羟萘酸盐晶型A在pH7.4介质振荡后)。
图22：描述在大鼠体中本发明实施例44制剂口服样品，卡利拉嗪的平均血药浓度与时间的关系图；
图23：描述在大鼠体内本发明实施例40-43制剂注射样品，卡利拉嗪的平均血药浓度与时间的关系图(■为卡利拉嗪双羟萘酸盐无定型；◆为卡利拉嗪双羟萘酸盐晶型A；●为卡利拉嗪双羟萘酸盐晶型B；▲为卡利拉嗪双羟萘酸盐晶型E)；
图24：图23的局部放大图(0～24小时卡利拉嗪的平均血药浓度与时间的关系图)(■为卡利拉嗪双羟萘酸盐无定型；◆为卡利拉嗪双羟萘酸盐晶型A；●为卡利拉嗪双羟萘酸盐晶型B；▲为卡利拉嗪双羟萘酸盐晶型E)。
具体实施方式
下面通过实施例的方式进一步说明本发明，但并不因此将本发明拘囿于所述实施例范围之中。下列实施例中未注明具体条件的实验方法，按照常规方法和条件，或按照商品说明书选择。
除非另有说明，下文实施例中的原料和试剂可通过商购获得，或由本领域技术人员根据本领域已知的方法制备获得。
分别采用核磁共振( 1H-NMR)、X-射线粉末衍射(XRPD)、差示扫描量热法(DSC)、热重分析(TGA)、热台偏正光显微镜(PLM)、高效液相色谱(HPLC)对实施例的盐型化合物进行测试，测试参数如下：
(1) 1H-NMR测试在布鲁克型号为Bruker Advance III 500M核磁共振谱仪中进行，测量频率为400Mz，使用溶剂为氘代DMSO。
(2)DSC测量在TA Instruments型号Q2000中密封盘装置进行，将样品(约1～2mg)在铝盘中称量，转移至仪器中进行测量。测试参数如下：仪器在30℃平衡，以10℃/min的速率升温至300℃，收集数据，实验气氛为氮气。
(3)TGA测量在TA Instruments型号Q500装置中进行，将样品(约2～5mg)在铝盘中称量，转移至仪器中进行测量。测试参数如下：仪器以10℃/min的速率升温至350℃，收集数据，实验气氛为氮气。
(4)XRPD测量在布鲁克型号为D8 Advance X-射线粉末衍射仪中进行，并使用圆形零背景的单晶硅样品台。扫描参数如下：电压40kv，电流40mA，扫描范围3°～45°，扫描步长0.02°，扫描模式为连续扫描。
(5)PLM测量在上海点应光学仪器型号为DYP990/TPH350的热台偏光显微镜中进行，取少量样品分散在载玻片中于10倍目镜以及5-40倍物镜中拍照。
(6)HPLC含量和有关物质检测方法：
含量方法：
Figure PCTCN2021114756-appb-000003
含量梯度洗脱程序表：
时间(min) 流动相A(％) 流动相B(％)
0 60 40
2 40 60
5 15 85
5.1 60 40
10 60 40
有关物质方法：
Figure PCTCN2021114756-appb-000004
Figure PCTCN2021114756-appb-000005
有关梯度洗脱程序表：
时间(min) 流动相A(％) 流动相B(％)
0 80 20
7 45 55
17 37 63
25 20 80
25.1 80 20
35 80 20
除非另有说明，本发明上下文中卡利拉嗪药物组合物混悬水溶液粒度检测仪器的检测条件如下：
进样器名称：SCF-105B                  物质名称：卡利拉嗪组合物
颗粒折射率：1.595                     分散剂折射率：1.333
分散剂：水                            背景测试时间：10s
样品测试时间：10s                     遮光度：10-20％
搅拌速度：700-2000r/min               分析模型：通用
测量范围：0.02-2100μm                颗粒吸收率：0.1
重复测量三次，创建平均值。
实施例1：卡利拉嗪双羟萘酸盐的制备
将4000mg(9.36mmol)卡利拉嗪溶于200mL(5.4mg/mL)磷酸溶液中，得到溶液A；将3634mg(9.36mmol)双羟萘酸溶于100mL(7.5mg/mL)氢氧化钠溶液中，得到溶液B。搅拌下将100mL溶液B于30分钟内加入200mL溶液A中，过滤分离产物并用水冲洗，40℃真空干燥12小时，得到5840mg浅黄色固体，收率为76％(以 游离碱计)。
通过核磁共振氢谱证实了本发明所述的卡利拉嗪双羟萘酸盐的结构及摩尔比。
1H-NMR(400MHz,DMSO-d6)：δ8.38(s,2H)，8.16(d,2H)，8.80(d,2H)，7.39-7.13(m,7H)，5.86(d,1H)，4.76(s,2H)，3.40-3.32(m,3H)，3.22-3.18(m,4H)，2.75(s,6H)，1.76(t,4H)，1.63-1.57(m,2H)，1.25-1.16(m,3H)，1.04-0.96(m,2H)。
核磁结果显示卡利拉嗪和双羟萘酸以摩尔比为1:1成盐。
上述样品进行固相表征检测，XRPD图谱见图1，检测结果显示为无定型。
实施例2：卡利拉嗪双羟萘酸盐无定型的制备
60℃条件下，将20g(46.8mmol)卡利拉嗪与18.17g(46.8mmol)双羟萘酸溶解于170mL THF:MeOH(2:1)混合溶剂中，过滤，减压浓缩除去溶剂，再加入300mL甲醇，60℃溶解，减压浓缩除去溶剂，40℃真空干燥12小时，得到36.6g卡利拉嗪双羟萘酸盐无定型。
实施例3：卡利拉嗪半双羟萘酸盐的制备
将200mg(0.468mmol)卡利拉嗪溶于10mL(5.4mg/mL)磷酸溶液中，得到溶液A；将90.85mg(0.234mmol)双羟萘酸溶于2.5mL(7.5mg/mL)氢氧化钠溶液中，得到溶液B。搅拌下将2.5mL溶液B于30分钟内加入10mL溶液A中，过滤分离产物并用水冲洗，40℃真空干燥12小时，得到204mg浅黄色固体，收率为70％。
通过核磁共振氢谱证实了本发明所述的卡利拉嗪双羟萘酸盐的结构及摩尔比。
1H-NMR(400MHz,DMSO-d6)：δ8.25(s,1H)，8.18(d,1H)，7.69(d,1H)，7.38-7.31(m,2H)，7.22-7.14(m,2H)，7.05(t,1H)，5.86(d,1H)，4.71(s,1H)，3.39-3.22(m,5H)，2.75(s,6H)，1.75(t,4H)，1.59-1.54(m,2H)，1.25-1.15(m,3H)，1.04-0.95(m,2H)。
核磁结果显示卡利拉嗪和双羟萘酸以摩尔比为2:1成盐。
上述样品进行PLM检测，显示该样品为无偏光固体，为无定型。
实施例4：卡利拉嗪1-羟基-2-萘甲酸盐的制备
将100mg(0.234mmol)卡利拉嗪与45mg(0.234mmol)1-羟基-2-萘甲酸加入8mL甲醇中，搅拌溶清，过滤，加入3倍体积的正庚烷，室温挥发至溶剂干，为油状物，40℃真空干燥4小时，得到固体。
PLM检测发现该固体具有偏光，在约200℃开始熔融。
1H-NMR(400MHz,DMSO-d6)：δ8.23(d,1H)，7.80-7.74(m,2H)，7.57-7.53(m,1H)，7.48-7.44(m,1H)，7.38-7.31(m,2H)，7.20-7.16(m,2H)，5.86(d,1H)，3.36-3.09(m,10H)，2.75(s,6H)，1.74(t,4H)，1.61-1.56(m,2H)，1.33-1.15(m,5H)，1.02-0.83(m,3H)。
核磁结果显示卡利拉嗪与1-羟基-2-萘甲酸以摩尔比为1:1成盐。
实施例5：卡利拉嗪月桂酸盐的制备
将50mg(0.117mmol)卡利拉嗪与23.7mg(0.118mmol)月桂酸加入5mL甲醇中，置于50℃条件下溶解，室温搅拌12小时，加入2倍体积的水，过滤，固体于40℃条件下真空干燥12小时，得到卡利拉嗪月桂酸盐。
实施例6：卡利拉嗪软脂酸盐的制备
将50mg(0.117mmol)卡利拉嗪与30.3mg(0.118mmol)软脂酸加入5mL甲醇中，置于50℃条件下溶解，室温搅拌12小时，加入1倍体积的水，过滤，固体于40℃条件下真空干燥12小时，得到卡利拉嗪软脂酸盐。
实施例7：卡利拉嗪癸二酸盐、卡利拉嗪琥珀酸盐、卡利拉嗪苹果酸盐、卡利拉嗪乳酸盐、卡利拉嗪十一烷酸盐、卡利拉嗪庚酸盐的制备
按照1:1.1的摩尔比称量卡利拉嗪与酸。将各种酸分别溶于甲醇溶剂，所得酸性试剂于室温条件下加入卡利拉嗪甲醇溶液中进行成盐反应。室温搅拌12小时后并置于室温下挥发、干燥得到相应的卡利拉嗪盐。
实施例8：卡利拉嗪双羟萘酸盐晶型A的制备
取2000mg实施例1制备得到的卡利拉嗪双羟萘酸盐，加入20mL甲醇中，室温 搅拌析晶24小时，过滤，55℃真空干燥，得到1900mg卡利拉嗪双羟萘酸盐晶型A，收率为95％。
其X射线粉末衍射图如图2所示。
其差式扫描量热分析图如图3所示，显示熔点为166.5℃。
其热重分析图如图4所示，显示在115℃之前有两段失重，归结于表面溶剂和通道水的损失，在115～165℃时，有约1.1％的失重，归结于结晶水的损失。
其核磁图如图5所示，显示卡利拉嗪与双羟萘酸以摩尔比1:1成盐。
实施例9：卡利拉嗪双羟萘酸盐晶型A的制备
取30g实施例2制备得到的卡利拉嗪双羟萘酸盐无定型固体样品，加入300mL甲醇中，10℃搅拌析晶24小时，过滤，55℃真空干燥，得到28.5g卡利拉嗪双羟萘酸盐晶型A。
实施例10：卡利拉嗪双羟萘酸盐晶型B的制备
取200mg实施例9所得的卡利拉嗪双羟萘酸盐晶型A在甲醇溶剂中形成浆液，卡利拉嗪双羟萘酸盐晶型A与溶剂的重量体积比为40mg/mL，搅拌3天析晶，得到180mg卡利拉嗪双羟萘酸盐晶型B。
其X射线粉末衍射图如图14所示。
核磁结果显示其为甲醇溶剂合物。
实施例11：卡利拉嗪双羟萘酸盐晶型B的制备
取2g实施例9制备得到的卡利拉嗪双羟萘酸盐晶型A，加入50mL甲醇中，室温搅拌析晶72小时，过滤，55℃真空干燥，得到1.9mg卡利拉嗪双羟萘酸盐晶型B。
实施例12：卡利拉嗪双羟萘酸盐晶型C的制备
取实施例8所得的卡利拉嗪双羟萘酸盐晶型A在丙酮溶剂中形成浆液，卡利拉嗪双羟萘酸盐晶型A与溶剂的重量体积比为40mg/mL，搅拌3天析晶，得到卡利拉嗪双羟萘酸盐晶型C。
其X射线粉末衍射图如图15所示。
核磁结果显示其为丙酮溶剂合物。
实施例13：卡利拉嗪双羟萘酸盐晶型D的制备
取200mg实施例8制备得到的卡利拉嗪双羟萘酸盐晶型A，加入2mL乙醇中，室温搅拌析晶48小时，过滤，55℃真空干燥，得到190mg卡利拉嗪双羟萘酸盐晶型D，收率为95％。
其X射线粉末衍射图如图10所示。
其差式扫描量热分析图如图11所示，显示熔点为164.6℃。
其热重分析图如图12所示，显示在190℃之前有约4％的失重，归结于水和乙醇的损失。
其核磁图如图13所示，显示卡利拉嗪与双羟萘酸以摩尔比1:1成盐，含约0.67个乙醇分子。
实施例14：卡利拉嗪双羟萘酸盐晶型E的制备
取实施例8所得的卡利拉嗪双羟萘酸盐晶型A在乙腈溶剂中形成浆液，卡利拉嗪双羟萘酸盐晶型A与溶剂的重量体积比为40mg/mL，搅拌3天析晶，得到卡利拉嗪双羟萘酸盐晶型E。
其X射线粉末衍射图如图16所示。
实施例15：卡利拉嗪双羟萘酸盐晶型E的制备
取2g实施例9制备得到的卡利拉嗪双羟萘酸盐晶型A，加入50mL乙腈中，室温搅拌析晶72小时，过滤，55℃真空干燥，得到1.8g卡利拉嗪双羟萘酸盐晶型E。
实施例16：卡利拉嗪双羟萘酸盐晶型F的制备
取200mg实施例8制备得到的卡利拉嗪双羟萘酸盐晶型A，加入20mL乙酸异丙酯中，室温搅拌析晶12小时，过滤，55℃真空干燥，得到180mg卡利拉嗪双羟萘酸盐晶型F，收率为90％。
其X射线粉末衍射图如图6所示。
其差式扫描量热分析图如图7所示，显示熔点约为166.6℃。
其热重分析图如图8所示，显示在115℃之前有约1.3％的失重，归结于通道水的损失；在115～175℃有约1.3％的失重，归结于结晶水的损失。
其核磁图如图9所示，显示卡利拉嗪与双羟萘酸以摩尔比1:1成盐。
实施例17：卡利拉嗪双羟萘酸盐晶型G的制备
取200mg实施例8所得的卡利拉嗪双羟萘酸盐晶型A，加入5mL乙腈形成浆液，搅拌5天析晶，得到卡利拉嗪双羟萘酸盐晶型G。
其X射线粉末衍射图如图17所示。
核磁结果显示其为乙腈溶剂合物。
实施例18：卡利拉嗪双羟萘酸盐晶型I的制备
取15mg实施例1所得的卡利拉嗪双羟萘酸盐无定型固体样品于光照条件下10天，得到卡利拉嗪双羟萘酸盐晶型I。
其X射线粉末衍射图如图18所示。
实施例19：卡利拉嗪盐酸盐晶型I的制备
根据卡利拉嗪盐酸盐原研专利制备卡利拉嗪盐酸盐晶型I样品：
1g市售卡利拉嗪游离碱加入25mL圆底烧瓶，加入2mL甲醇与8mL水，70℃油浴锅搅拌0.5h，加入0.226mL浓盐酸与0.35mL水的混合溶液，溶清后趁热过滤，关闭加热自然冷却过夜，收得0.8g类白色固体。
其X射线粉末衍射图如图19所示，显示为卡利拉嗪盐酸盐晶型I。
对比例1：有关物质与晶型稳定性对比
分别取实施例1制得的卡利拉嗪双羟萘酸盐无定型、实施例8制得的卡利拉嗪双羟萘酸盐晶型A、实施例10制得的卡利拉嗪双羟萘酸盐晶型B、实施例16制得的卡利拉嗪双羟萘酸盐晶型F、实施例17制得的卡利拉嗪双羟萘酸盐晶型G、实施例19制得的 卡利拉嗪盐酸盐晶型I于高温(60℃)，高湿(25℃/90％RH)，加速(40℃/75％RH)，光照(1.2×10 6Lux·hr)条件下放置，于0天、5天、7天、10天取样进行HPLC或XRPD检测。
有关物质结果见表1，显示本发明的卡利拉嗪双羟萘酸盐晶型A、卡利拉嗪双羟萘酸盐晶型B和卡利拉嗪双羟萘酸盐晶型G，卡利拉嗪双羟萘酸盐晶型A较稳定，在各条件下放置10天，有关物质总和基本不变，而卡利拉嗪双羟萘酸盐无定型在高温条件下不稳定，杂质增长较多。
晶型稳定性结果见表2，其显示与已知的卡利拉嗪盐酸盐晶型I相比，本发明的卡利拉嗪双羟萘酸盐晶型A具有更优异的晶型稳定性，在各条件下放置10天，晶型未变，结晶度也未明显变化；本发明的卡利拉嗪双羟萘酸盐晶型F在高温和光照条件下较稳定，晶型未发生变化，在高湿和加速条件会向卡利拉嗪双羟萘酸盐晶型A转变。
表1有关物质结果
Figure PCTCN2021114756-appb-000006
表2晶型稳定性结果
Figure PCTCN2021114756-appb-000007
Figure PCTCN2021114756-appb-000008
对比例2：溶解度对比
分别取实施例1制得的卡利拉嗪双羟萘酸盐无定型、实施例3制得的卡利拉嗪半双羟萘酸盐无定型、实施例5制得的卡利拉嗪月桂酸盐、实施例6制得的卡利拉嗪软脂酸盐、实施例7制得的卡利拉嗪癸二酸盐、卡利拉嗪琥珀酸盐、卡利拉嗪苹果酸盐、卡利拉嗪乳酸盐、卡利拉嗪十一烷酸盐、卡利拉嗪庚酸盐、实施例8制得的卡利拉嗪双羟萘酸盐晶型A、实施例10制得的卡利拉嗪双羟萘酸盐晶型B、实施例16制得的卡利拉嗪双羟萘酸盐晶型F、实施例17制得的卡利拉嗪双羟萘酸盐晶型G、实施例19制备的卡利拉嗪盐酸盐晶型I、卡利拉嗪将其分别加入到相应介质中，在37℃条件下振荡24小时，0.45μm水相滤膜过滤，收集滤液，采用高效液相进行溶解度测定。其中，pH3、pH4、pH5和pH6为醋酸缓冲溶液、pH7、pH7.4、pH8和pH9为磷酸缓冲溶液。
结果见表3，显示本发明制得的卡利拉嗪双羟萘酸盐及其晶型与半双羟萘酸盐的溶解度均大幅低，卡利拉嗪双羟萘酸盐在水中的溶解度为3～10μg/mL相当于卡利拉嗪的十八分之一至六十分之一(约180μg/mL)，盐酸卡利拉嗪的千分之一至三千六百分之一(约11mg/mL)，以及在各个pH介质中均较低，本身就具有缓释作用，同时在各个pH介质中的溶解度相当，释放速度可以最小程度的依赖于pH，从而避免在体内不同区域的pH环境中对其释药速率的影响，避免造成突释现象或体内局部区域血药浓度过高，以及降低个体间释药差异性，且卡利拉嗪双羟萘酸盐的晶型稳定性较好，适合用于长效制剂可减少用药次数，提高患者用药依从性，市场化前景良好。
表3溶解度结果
Figure PCTCN2021114756-appb-000009
Figure PCTCN2021114756-appb-000010
对比例3：体外溶出模拟实验
分别取实施例1制得的卡利拉嗪双羟萘酸盐无定型、实施例8制得的卡利拉嗪双羟萘酸盐晶型A、实施例10制得的卡利拉嗪双羟萘酸盐晶型B、实施例17制得的卡利拉嗪双羟萘酸盐晶型G，将其分别加入到pH7.4磷酸缓冲溶液介质中，在37℃条件下振荡，于1、3、5、7、24小时取点检测溶解度。
结果见表4与图20，其显示本发明制得的卡利拉嗪双羟萘酸盐晶型A与卡利拉嗪双羟萘酸盐晶型B两种晶型化合物样品较卡利拉嗪双羟萘酸盐无定型样品在pH7.4条件下溶出更平缓且24小时溶解度小，说明晶型化合物更适合作为药用盐，避免血药浓度过高。
表4体外溶出模拟实验结果
Figure PCTCN2021114756-appb-000011
对比例4：溶液稳定性对比
分别取实施例8制得的卡利拉嗪双羟萘酸盐晶型A、实施例19制得的卡利拉嗪盐酸盐晶型I，将其分别加入到pH6、pH7、pH7.4、pH8、pH9等相应介质中，在37℃条件下振荡4小时，离心，对残渣进行XRPD检测，结果显示卡利拉嗪双羟萘酸盐晶型A并未发生变化，而卡利拉嗪盐酸盐晶型I解离为卡利拉嗪游离碱，pH7.4对比结果见图21(其余未示出)，由此可见，卡利拉嗪双羟萘酸盐晶型A在溶液中较卡利拉嗪盐酸盐晶型I更稳定，可有效避免给药后因晶型的变化引起的药效改变，提高用药的安全性。
实施例20-25：不同助悬剂用量的卡利拉嗪双羟萘酸盐混悬水溶液
Figure PCTCN2021114756-appb-000012
制备过程：
(1)称取处方量吐温20、磷酸氢二钠、磷酸二氢钠、甘露醇与约60％配制总量的注射用水中，搅拌溶解分散；
(2)加入处方量的卡利拉嗪双羟萘酸盐晶型A，得到粗颗粒的混悬水溶液；
(3)将上述粗颗粒混悬水溶液使用球磨机研磨，得到Dv(90)小于等于10微米的混悬液；
(4)分别加入处方量的羧甲基纤维素钠至上述混悬液中，搅拌至完全分散，可选地用氢氧化钠或盐酸调节pH为4.0～9.0，定容，即得实施例20-25混悬液。
分别取实施例20-25所制得的处方样品，进行通针性、混悬性、沉降比以及重分散性考察，发现上述混悬液样品均可通过0.45*15mm注射器针头，混悬性良好，实施例22-25样品24小时沉降比及重分散性良好。
实施例26-30：不同润湿剂用量的卡利拉嗪双羟萘酸盐混悬水溶液
Figure PCTCN2021114756-appb-000013
Figure PCTCN2021114756-appb-000014
制备过程：
(1)称取处方量吐温20、磷酸氢二钠、磷酸二氢钠、甘露醇与约60％配制总量的注射用水中，搅拌溶解分散；
(2)加入处方量的卡利拉嗪双羟萘酸盐晶型A，得到粗颗粒的混悬水溶液；
(3)分别将上述粗颗粒混悬水溶液使用球磨机研磨，得到Dv(90)小于等于10微米的混悬液；
(4)分别加入处方量的羧甲基纤维素钠至上述混悬液中，搅拌至完全分散，可选地用氢氧化钠或盐酸调节pH为4.0～9.0，定容，即得实施例26-30混悬液。
分别取实施例26-30所制得的处方样品，进行通针性、混悬性、沉降比以及润湿性考察，发现上述混悬液样品均可通过0.45*15mm注射器针头，混悬性、沉降比以及润湿性均良好。
实施例31-34：不同粒径卡利拉嗪双羟萘酸盐混悬水溶液
Figure PCTCN2021114756-appb-000015
Figure PCTCN2021114756-appb-000016
制备过程：
(1)称取处方量吐温20、磷酸氢二钠、磷酸二氢钠、甘露醇与约60％配制总量的注射用水中，搅拌溶解分散；
(2)加入处方量的卡利拉嗪双羟萘酸盐晶型A，得到粗颗粒的混悬水溶液；
(3)分别将上述实施例31-34所得粗颗粒混悬水溶液使用球磨机研磨分散；
(4)分别加入处方量的羧甲基纤维素钠至上述混悬液中，搅拌至完全分散，定容，即得pH7.4±0.2的实施例31-34混悬液；
(5)采用OMEC LS-909粒度测定仪测定研磨后实施例样品粒度分布，结果见下表：
Figure PCTCN2021114756-appb-000017
根据上表结果可知，同样处方的混悬水溶液中，通过控制研磨参数，可制备出不同粒径大小(Dv90)颗粒的混悬水溶液。
实施例35-37：不同晶型卡利拉嗪双羟萘酸盐混悬水溶液
Figure PCTCN2021114756-appb-000018
制备过程：
(1)称取处方量吐温20、磷酸氢二钠、磷酸二氢钠、甘露醇与约60％配制总量的注射用水中，搅拌溶解分散；
(2)分别加入处方量的卡利拉嗪双羟萘酸盐相应样品，得到粗颗粒的混悬水溶液；
(3)分别将上述实施例35-37所得粗颗粒混悬水溶液使用球磨机研磨分散；
(4)分别加入处方量的羧甲基纤维素钠至上述混悬液中，搅拌至完全分散，定容，即得pH7.4±0.2的实施例35-37混悬液；
(5)采用OMEC LS-909粒度测定仪测定研磨后实施例样品粒度分布，结果见下表：
Figure PCTCN2021114756-appb-000019
分别取实施例35-37所制得的处方样品，进行通针性、混悬性、沉降比以及润湿性考察，发现上述混悬液样品均可通过0.45*15mm注射器针头，混悬性、沉降比以及润湿性均良好。
根据上表结果以及通针性、混悬性、沉降比与润湿性考察，同样处方的混选水溶液中以及相同研磨参数，对于卡利拉嗪双羟萘酸盐的不同晶型均适用。
实施例38：卡利拉嗪盐酸盐混悬水溶液
Figure PCTCN2021114756-appb-000020
制备过程：
(1)称取处方量吐温20、磷酸氢二钠、磷酸二氢钠、甘露醇与约60％配制总量的注射用水中，搅拌溶解分散；
(2)加入处方量的卡利拉嗪盐酸盐，得到粗颗粒的混悬水溶液；
(3)将上述所得粗颗粒混悬水溶液使用球磨机研磨分散；
(4)加入处方量的羧甲基纤维素钠至上述混悬液中，搅拌至完全分散，定容，即得pH7.4±0.2的实施例38混悬液；
(5)采用OMEC LS-909粒度测定仪测定研磨后实施例样品粒度分布，结果见下表：
Figure PCTCN2021114756-appb-000021
实施例39：卡利拉嗪双羟萘酸盐与卡利拉嗪盐酸盐混悬水溶液60℃稳定性考察
取实施例33制备所得卡利拉嗪双羟萘酸盐以及实施例38制备所得卡利拉嗪盐酸盐混悬水溶液于60℃条件下检测0、5、10天的粒径与有关，结果见下表：
Figure PCTCN2021114756-appb-000022
根据上表结果可知，同样处方的混悬水溶液中，卡利拉嗪双羟萘酸盐混悬水溶液在杂质以及粒径的稳定性方面均明显优于卡利拉嗪盐酸盐混悬水溶液稳定。
实施例40-44：卡利拉嗪双羟萘酸盐混悬液处方在大鼠体内的药物动力学研究
Figure PCTCN2021114756-appb-000023
Figure PCTCN2021114756-appb-000024
1、实施例40-43混悬注射液制备过程：
(1)称取处方量吐温20、磷酸氢二钠、磷酸二氢钠、甘露醇、羧甲基纤维素钠与约60％配制总量的注射用水中，搅拌溶解分散；
(2)分别加入处方量的卡利拉嗪双羟萘酸盐相应样品，搅拌至完全分散，定容，即得pH7.4±0.2的实施例40-43混悬注射液；
(3)采用OMEC LS-909粒度测定仪测定实施例41-43样品粒度分布，结果见下表：
Figure PCTCN2021114756-appb-000025
2、实施例44口服混悬液制备过程：
(1)称取处方量的吐温20、羧甲基纤维素钠与约60％配制总量的注射用水中，搅拌溶解分散；
(2)加入处方量的卡利拉嗪双羟萘酸盐，得到粗颗粒的混悬水溶液，用盐酸调节pH为5.0至5.5，定容，得到最终实施例44的混悬口服液。
实施例45：药代动力学实验
选择实施例40-44制备所得不同浓度卡利拉嗪双羟萘酸盐处方样品，进行大鼠体内实验，实验如下：
15只雄性SD大鼠分为五组，其中四组单剂量9mg/kg经肌肉注射给予不同卡利拉嗪双羟萘酸盐晶型处方样品，并于给药后0,1h,3h,7h,24h,4d,7d,11d,15d,20d,25d,30d采集血浆；剩余一组单剂量0.3mg/kg经口服灌胃给予卡利拉嗪双羟萘酸盐晶型A处方样品，并于给药后5min,15min,30min,1,2,3,4,6,8,12和24小时，采集血浆。整个试验中，肌肉注射组动物自由饮食饮水，口服灌胃组给药前禁食过夜，给药后4小时恢复饮食。
血浆样品采集：颈静脉采血约150μL(全血在30分钟内离心分离血浆)置于内含抗凝剂EDTA-K2的试管内，经处理后血浆保存于-70℃冰箱待用。
血浆样品预处理：取30μL血浆样品中加入200μL内标溶液(40ng/mL Glipizide乙腈溶液)，涡旋混合1min，在4℃下以5800rpm离心10min，取100μL上清液转移至新板，取1μL溶液进行LC-MS/MS分析。
色谱条件：
流动相组成：流动相A：0.025％甲酸水-1mM乙酸铵
           流动相B：0.025％甲酸甲醇-1mM乙酸铵
梯度洗脱：
时间(分钟) Pump B(％)
初始 10
0.20 10
0.70 95
1.30 95
1.31 10
1.80 10
色谱柱：Waters ACQUITY UPLC BEH C18(2.1×50mm,1.7μm)；
流速：0.60mL/min；
进样体积：1μL；
柱温箱：60℃；
保留时间：卡利拉嗪：1.16min；Glipizide：1.22min。
质谱条件：
采用电喷雾离子源(Turbo spray)，在正离子检测模式下，选择多通道反应监测(MRM)模式进行二级质谱分析。质谱检测工作参数及离子源参数见下表。
Figure PCTCN2021114756-appb-000026
从图22-24中可以看出，卡利拉嗪双羟萘酸盐口服组在给药后24小时内快速吸收，而卡利拉嗪双羟萘酸盐注射组给药后较口服组均达到至少11天的持续释放，结合种属间差异，预计在人体中可达至少30天释放。同时，在卡利拉嗪双羟萘酸盐各晶型之间以卡利拉嗪双羟萘酸盐晶型A释放时长为最优。
根据本发明的实验结果可知，本发明提供的卡利拉嗪双羟萘酸盐注射制剂在制备成混悬水溶液后，其中卡利拉嗪双羟萘酸盐粒度较小，分布均匀，具有良好的可注射性，同时具有长时间持续释放药物的特征(在SD大鼠体内至少一周时间)。

Claims (10)

  1. 一种卡利拉嗪药用盐，其特征在于：所述的卡利拉嗪药用盐选自卡利拉嗪游离碱与六个碳以上的有机酸形成的盐；
    Figure PCTCN2021114756-appb-100001
    优选地，所述的六个碳以上的有机酸为C 6～C 30的有机酸；
    例如，所述的C 6～C 30的有机酸包括但不限于：己酸、庚酸、辛酸、壬酸、壬二酸、癸酸、十一烷酸、月桂酸、十三烷酸、肉豆蔻酸、十五烷酸、棕榈酸、十七烷酸、硬脂酸、十九烷酸、二十烷酸、油酸、二十一烷酸、二十二烷酸、二十三烷酸、二十四烷酸、二十五烷酸、二十六烷酸、二十七烷酸、二十八烷酸、二十九烷酸、三十烷酸、甘油三乙酸、木质酸、双羟萘酸、1-羟基-2萘甲酸以及萘酸衍生物。
    优选地，所述的萘酸衍生物包括但不限于萘酸酯。
  2. 如权利要求1所述的卡利拉嗪药用盐，其特征在于：所述的卡利拉嗪药用盐选自晶体、多晶或无定型的形式，或其与溶剂形成的溶剂合物；
    优选地，所述的溶剂合物包括卡利拉嗪药用盐的水合物和卡利拉嗪药用盐与有机溶剂形成的溶剂合物。
  3. 如权利要求1所述的卡利拉嗪药用盐，其特征在于：所述的药用盐中卡利拉嗪与所述的六个碳以上的有机酸的摩尔比为(1：0.5)～(1：2)。
  4. 如权利要求1所述的卡利拉嗪药用盐，其特征在于：所述的“卡利拉嗪药用盐与有机溶剂形成的溶剂合物”中所述的“有机溶剂”选自乙醇、丙酮、二甲基亚砜及其混合物。
  5. 如权利要求1所述的卡利拉嗪药用盐，其特征在于：所述的卡利拉嗪药用盐选自下列自卡利拉嗪双羟萘酸盐的晶型A、F、D、B、C、E、G和I：
    所述的卡利拉嗪双羟萘酸盐晶型A的X射线粉末衍射图在2θ值为13.1°±0.2°、18.7°±0.2°、21.0°±0.2°等处有特征峰，优选在2θ值为4.8°±0.2°、13.1°±0.2°、18.7°±0.2°、20.1°±0.2°、21.0°±0.2°、26.1°±0.2°等处有特征峰；更优选在2θ值为4.8°±0.2°、9.7±0.2°、12.3°±0.2°、13.1°±0.2°、18.7°±0.2°、20.1°±0.2°、21.0°±0.2°、26.1°±0.2°等处有特征峰；
    所述的卡利拉嗪双羟萘酸盐晶型F的X射线粉末衍射图在2θ值为4.9°±0.2°、19.2°±0.2°、21.0°±0.2°等处有特征峰；优选在2θ值为4.9°±0.2°、13.6°±0.2°、19.2°±0.2°、21.0°±0.2°、24.0°±0.2°、26.3°±0.2°等处有特征峰；更优选在2θ值为4.9°±0.2°、12.8°±0.2°、13.6°±0.2°、19.2°±0.2°、20.3°±0.2°、21.0°±0.2°、24.0°±0.2°、26.3°±0.2°等处有特征峰；
    所述的卡利拉嗪双羟萘酸盐晶型D的X射线粉末衍射图在2θ值为9.6°±0.2°、11.9°±0.2°、20.4°±0.2°等处有特征峰；优选在2θ值为9.6°±0.2°、11.9°±0.2°、16.6°±0.2°、20.4°±0.2°、24.5°±0.2°、25.3°±0.2°等处有特征峰；更优选在2θ值为9.6°±0.2°、11.9°±0.2°、15.2°±0.2°、16.6°±0.2°、20.4°±0.2°、20.7°±0.2°、24.5°±0.2°、25.3°±0.2°等处有特征峰；
    所述的卡利拉嗪双羟萘酸盐晶型B的X射线粉末衍射图在2θ值为5.2°±0.2°、10.5°±0.2°、14.0°±0.2°、14.4°±0.2°、17.5°±0.2°、21.3°±0.2°、21.9°±0.2°、22.9°±0.2°、26.2°±0.2°等处有特征峰；
    所述的卡利拉嗪双羟萘酸盐晶型C的X射线粉末衍射图在2θ值为8.6°±0.2°、13.0°±0.2°、16.8°±0.2°、17.3°±0.2°、18.2°±0.2°、18.5°±0.2°、19.8°±0.2°、22.1°±0.2°、23.5°±0.2°等处有特征峰；
    所述的卡利拉嗪双羟萘酸盐晶型E的X射线粉末衍射图在2θ值为11.0°±0.2°、12.8°±0.2°、13.8°±0.2°、15.5°±0.2°、15.9°±0.2°、17.9°±0.2°、18.4°±0.2°、20.7°±0.2°、23.4°±0.2°等处有特征峰；
    所述的卡利拉嗪双羟萘酸盐晶型G的X射线粉末衍射图在2θ值为8.7°±0.2°、10.0°±0.2°、13.6°±0.2°、14.3°±0.2°、17.5°±0.2°、18.0°±0.2°、20.3°±0.2°、23.2°±0.2°、25.1°±0.2°等处有特征峰；
    所述的卡利拉嗪双羟萘酸盐晶型I的X射线粉末衍射图在2θ值为10.0°±0.2°、14.9°±0.2°、16.3°±0.2°、17.7°±0.2°、18.5°±0.2°、19.0°±0.2°、21.1°±0.2°、22.1°±0.2°、24.5°±0.2°等处有特征峰的至少一种。
  6. 如权利要求1-5任一项所述的卡利拉嗪药用盐的制备方法，包括以下步骤：将卡利拉嗪游离碱与所述的六个碳以上的有机酸进行反应，得到所述的卡利拉嗪药用盐。
  7. 一种药物组合物，其特征在于包括权利要求1-5任一项所述的卡利拉嗪药用盐。
  8. 如权利要求1-5任一项所述的卡利拉嗪药用盐在制备治疗和/或预防精神病、双相性障碍和/或急性躁狂症的药物中的应用。
  9. 如权利要求8所述的应用，其特征在于：所述的药物的剂型选自片剂、胶囊、溶液剂、混悬剂、长效注射剂和半固体制剂。
  10. 如权利要求9所述的应用，其特征在于：所述的混悬剂为水混悬剂、油混悬剂或混悬粉末。
PCT/CN2021/114756 2020-08-26 2021-08-26 卡利拉嗪药用盐及其晶型、制备方法和应用 WO2022042643A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US18/043,000 US20230355612A1 (en) 2020-08-26 2021-08-26 Pharmaceutically acceptable salt of cariprazine and crystal form thereof, and preparation method therefor and use thereof
JP2023513724A JP2023540056A (ja) 2020-08-26 2021-08-26 カリプラジン薬用塩及びその結晶形、製造方法及び応用
EP21860477.5A EP4206191A1 (en) 2020-08-26 2021-08-26 Pharmaceutically acceptable salt of cariprazine and crystal form thereof, and preparation method therefor and use thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
CN202010870701.6 2020-08-26
CN202010869671.7 2020-08-26
CN202010870701 2020-08-26
CN202010869671 2020-08-26
CN202110324874 2021-03-26
CN202110330670.X 2021-03-26
CN202110330670 2021-03-26
CN202110324874.2 2021-03-26

Publications (1)

Publication Number Publication Date
WO2022042643A1 true WO2022042643A1 (zh) 2022-03-03

Family

ID=80352733

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/CN2021/114756 WO2022042643A1 (zh) 2020-08-26 2021-08-26 卡利拉嗪药用盐及其晶型、制备方法和应用
PCT/CN2021/114754 WO2022042642A1 (zh) 2020-08-26 2021-08-26 卡利拉嗪药物组合物、制备方法及应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/CN2021/114754 WO2022042642A1 (zh) 2020-08-26 2021-08-26 卡利拉嗪药物组合物、制备方法及应用

Country Status (6)

Country Link
US (2) US20230414504A1 (zh)
EP (2) EP4205745A1 (zh)
JP (2) JP2023540056A (zh)
CN (3) CN114195740B (zh)
TW (2) TW202216672A (zh)
WO (2) WO2022042643A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174382A1 (en) * 2022-03-17 2023-09-21 Anxo Pharmaceutical Co., Ltd. Injectable depot formulation comprising cariprazine free base particles

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116675654A (zh) * 2022-02-22 2023-09-01 上海云晟研新生物科技有限公司 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008139235A2 (en) * 2007-05-11 2008-11-20 Richter Gedeon Nyrt. Novel piperazine salts as d3/d2 antagonists
CN101801381A (zh) * 2007-05-11 2010-08-11 里克特格德翁公司 新型氨基甲酰基-环己烷衍生物的溶剂合物和结晶形式
CN105218484A (zh) 2015-09-14 2016-01-06 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106543105A (zh) * 2015-09-22 2017-03-29 江苏恩华药业股份有限公司 一种盐酸卡利拉嗪晶型ⅳ及其制备方法
WO2020056929A1 (zh) 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
US8658687B2 (en) * 2009-06-24 2014-02-25 Merck Sharp & Dohme Corp. Injectable formulations containing asenapine and method of treatment using same
CN106560179B (zh) * 2015-09-30 2020-02-21 石药集团中奇制药技术（石家庄）有限公司 盐酸卡利拉嗪药物组合物及其制备方法
CN106699689A (zh) * 2015-11-13 2017-05-24 天津市汉康医药生物技术有限公司 一种卡利拉嗪三水合物化合物
CN108261394B (zh) 2017-01-04 2022-03-04 广东东阳光药业有限公司 一种盐酸卡利拉嗪注射制剂及其制备方法和用途
CN106831594B (zh) * 2017-01-18 2018-02-02 力赛生物医药科技（厦门）有限公司 可乐定双羟萘酸盐及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008139235A2 (en) * 2007-05-11 2008-11-20 Richter Gedeon Nyrt. Novel piperazine salts as d3/d2 antagonists
CN101679315A (zh) 2007-05-11 2010-03-24 吉瑞工厂 作为d3/d2拮抗剂的新型哌嗪盐
CN101801381A (zh) * 2007-05-11 2010-08-11 里克特格德翁公司 新型氨基甲酰基-环己烷衍生物的溶剂合物和结晶形式
CN105218484A (zh) 2015-09-14 2016-01-06 安徽省逸欣铭医药科技有限公司 酒石酸卡利拉嗪及其制备方法和医药用途
CN106543105A (zh) * 2015-09-22 2017-03-29 江苏恩华药业股份有限公司 一种盐酸卡利拉嗪晶型ⅳ及其制备方法
WO2020056929A1 (zh) 2018-09-21 2020-03-26 上海诚妙医药科技有限公司 卡利拉嗪盐酸盐的新晶型及其制备方法及其用途

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAS, no. 130-85-8
HAO, CHAO ET AL.: "A New Polymorphic Form of Cariprazine Hydrochloride", CHINESE JOURNAL OF PHARMACEUTICALS, vol. 49, no. 6, 31 December 2018 (2018-12-31), pages 830 - 834, XP055905914 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023174382A1 (en) * 2022-03-17 2023-09-21 Anxo Pharmaceutical Co., Ltd. Injectable depot formulation comprising cariprazine free base particles

Also Published As

Publication number Publication date
CN114195740A (zh) 2022-03-18
CN114099512B (zh) 2023-03-31
CN116139080A (zh) 2023-05-23
JP2023540056A (ja) 2023-09-21
CN114099512A (zh) 2022-03-01
US20230414504A1 (en) 2023-12-28
EP4206191A1 (en) 2023-07-05
WO2022042642A1 (zh) 2022-03-03
JP2023539298A (ja) 2023-09-13
EP4205745A1 (en) 2023-07-05
TW202216672A (zh) 2022-05-01
CN114195740B (zh) 2023-11-14
TW202216146A (zh) 2022-05-01
US20230355612A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
WO2022042643A1 (zh) 卡利拉嗪药用盐及其晶型、制备方法和应用
WO2022121670A1 (zh) Tolebrutinib的晶型及其制备方法和用途
CA3035124A1 (en) Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof
CN112047892A (zh) 一种吉非替尼与3-羟基苯甲酸共晶体
WO2018103726A1 (zh) 一种溴结构域蛋白抑制剂药物的晶型及其制备方法和用途
WO2018133705A1 (zh) Gft-505的晶型及其制备方法和用途
WO2022042641A1 (zh) 恩替卡韦药用盐及其制备方法、药物组合物和应用
WO2021249367A1 (zh) 二氮杂双环类化合物的对甲苯磺酸盐新晶型及其制备方法
WO2023160583A1 (zh) 卡利拉嗪药用盐及其晶型、药物组合物、制备方法和用途
TWI816411B (zh) 芬戈莫德的鹽的晶型、含其的藥物組合物及應用
WO2022199707A1 (zh) 哌马色林药用盐、制备方法、含其的药物组合物及应用
WO2022199708A1 (zh) 卢美哌隆药用盐、制备方法、含其的药物组合物及应用
CN114685438B (zh) 一种阿昔替尼苹果酸新盐
CN114685466B (zh) 一种阿昔替尼共晶盐
CN112851643B (zh) 嘧啶苯甲酰胺化合物的盐酸盐及其用途
CN113943270B (zh) 一种阿昔替尼晶型
CA3170562A1 (en) Salts and polymorphic forms of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1h-pyrazol-4-yl)-3h-imidazo[4,5-b]pyridine
WO2018059531A1 (zh) 一种腺苷a2a受体拮抗剂药物的晶型及其制备方法和用途
WO2019105388A1 (zh) 一种a3腺苷受体激动剂药物的晶型及其制备方法和用途
TW202216726A (zh) 八氫噻吩并喹啉化合物之琥珀酸鹽及其結晶
WO2018054359A1 (zh) 一种喹唑啉衍生物的盐、其制备方法及应用
WO2019011336A1 (zh) Qaw-039的晶型及其制备方法和用途
CN113943271A (zh) 一种阿昔替尼晶型及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21860477

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2023513724

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021860477

Country of ref document: EP

Effective date: 20230327